Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035347
Status:
COMPLETED
Last Update Posted:
2017-03-10
First Post:
2002-05-02
Brief Title:
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Randomized Multicenter Open Label Trial Comparing Intravenous Zithromax Azithromycin Plus Intravenous Rocephin Ceftriaxone Followed By Oral Zithromax Azithromycin With Intravenous Levaquin Levofloxacin Followed By Oral Levaquin Levofloxacin For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired Pneumonia
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens After written informed consent is obtained patients will receive one of the following two treatment regimens 1 intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets or 2 intravenous administration of levofloxacin followed by levofloxacin tablets At least four study visits are normally conducted up to approximately one month after starting therapy The objective of this study is to compare the safety and efficacy of the two treatment regimens
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None